My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 582

    1.

    The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.

    Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW.

    Diabetes. 2005 Apr;54(4):1100-7.PMID: 15793249 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

    Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

    Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.

    Rodriguez LM, Mason KJ, Haymond MW, Heptulla RA.

    Pediatr Res. 2007 Dec;62(6):746-9.PMID: 17957149 [PubMed - indexed for MEDLINE]Related articles

    4.

    Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

    Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR.

    Diabetes Care. 2003 Jan;26(1):1-8.PMID: 12502651 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

    Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG.

    Metabolism. 2002 May;51(5):636-41.PMID: 11979398 [PubMed - indexed for MEDLINE]Related articles

    6.

    Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus.

    Hassan K, Heptulla RA.

    Pediatr Diabetes. 2009 Jun;10(4):264-8. Epub 2008 Dec 18.PMID: 19140902 [PubMed - indexed for MEDLINE]Related articles

    7.

    Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

    Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.

    Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):55-60.PMID: 14737746 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.

    Orskov L, Nyholm B, Yde Hove K, Gravholt CH, Møller N, Schmitz O.

    Diabet Med. 1999 Oct;16(10):867-74.PMID: 10547215 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

    Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A.

    Diabetologia. 1996 Apr;39(4):492-9.PMID: 8778001 [PubMed - indexed for MEDLINE]Related articles

    10.

    Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia.

    Heptulla RA, Rodriguez LM, Mason KJ, Haymond MW.

    J Clin Endocrinol Metab. 2009 May;94(5):1608-11. Epub 2009 Feb 3.PMID: 19190104 [PubMed - indexed for MEDLINE]Related articles

    11.

    The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.

    Nyholm B, Orskov L, Hove KY, Gravholt CH, Møller N, Alberti KG, Moyses C, Kolterman O, Schmitz O.

    Metabolism. 1999 Jul;48(7):935-41.PMID: 10421239 [PubMed - indexed for MEDLINE]Related articles

    12.

    Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.

    Singh-Franco D, Robles G, Gazze D.

    Clin Ther. 2007 Apr;29(4):535-62. Review.PMID: 17617279 [PubMed - indexed for MEDLINE]Related articles

    13.

    The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.

    Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG.

    Horm Metab Res. 2002 Sep;34(9):504-8.PMID: 12384827 [PubMed - indexed for MEDLINE]Related articles

    14.

    Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.

    Chase HP, Lutz K, Pencek R, Zhang B, Porter L.

    J Pediatr. 2009 Sep;155(3):369-73. Epub 2009 May 21.PMID: 19464026 [PubMed - indexed for MEDLINE]Related articles

    15.

    Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.

    Kovatchev BP, Crean J, McCall A.

    Diabetes Technol Ther. 2008 Oct;10(5):391-6.PMID: 18715216 [PubMed - indexed for MEDLINE]Related articles

    16.

    Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

    Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG.

    Diabetes Care. 2003 Mar;26(3):784-90.PMID: 12610038 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue.

    Kolterman OG, Gottlieb A, Moyses C, Colburn W.

    Diabetes Care. 1995 Aug;18(8):1179-82.PMID: 7587855 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.

    Ceriello A, Piconi L, Quagliaro L, Wang Y, Schnabel CA, Ruggles JA, Gloster MA, Maggs DG, Weyer C.

    Diabetes Care. 2005 Mar;28(3):632-7.PMID: 15735200 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.

    Ryan GJ, Jobe LJ, Martin R.

    Clin Ther. 2005 Oct;27(10):1500-12. Review.PMID: 16330288 [PubMed - indexed for MEDLINE]Related articles

    20.

    Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.

    Edelman SV, Weyer C.

    Diabetes Technol Ther. 2002;4(2):175-89. Review.PMID: 12079621 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity